Eli Lilly posts stronger-than-expected Q3 earnings.
Pharmaceutical giant Eli Lilly posted stronger-than-expected third-quarter earnings and revenue on Thursday, fuelled by surging demand for its diabetes drug Mounjaro and weight-loss treatment Zepbound.
Source: Sharecast
Eli Lilly said revenues jumped 54% year-on-year to $17.6bn, with US sales up 45% to $11.3bn, driven by a 60% increase in prescription volumes. Net income rose to $5.58bn, or $6.21 per share, from $970m a year earlier, while adjusted earnings came in at $7.02 per share.
Mounjaro generated $6.52bn in revenue, up 109% and well ahead of forecasts, while Zepbound rose 184% to $3.59bn, slightly beating expectations.
Eli Lilly also raised its full-year guidance, with the firm now expecting revenue to be between $63bn and $63.5bn and adjusted profits to be $23–$23.70 per share. It also noted that its outlook reflects current US tariffs, but excluded potential new levies on imported pharmaceuticals.
As of 1430 GMT, Eli Lilly shares were up 0.85% at $820.45 each.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
